Heligenics AND Jackson Laboratory Announce New Collaboration on ERBB2 Breast Cancer Gene


Heligenics, Inc. today announced a new collaboration with the Jackson Laboratory. This joint project will make available the functional output of variants of unknown significance in a key part of the ERBB2 gene via the JAX clinical knowledge base, a digital resource that connects clinicians and researchers around the world to interpret complex genomic profiles of the Cancer.

“This is a fabulous partnership that will help modernize and expand the interpretation of variants for key cancer genes,” said Dr. Martin R. Schiller, CEO of Heligenics. “JAX brings a lot to the table and is a valuable partner.”

Heligenics’ proprietary GigaAssay process measures the causal functional impact of all mutants in a gene within 4-5 months, while it takes decades for other technologies to identify a single marker. This collaboration will lead to future clinical trials, research grants and publications to advance the fight against cancer, offering patients hope in identifying exploitable ERBB2 variants for potential treatment.

CKB currently provides a wealth of information relevant to the interpretation of cancer-related genomic data, including thousands of descriptions of gene variants, therapies, as well as evidence of therapeutic efficacy, accessible through a web application.

JAX-CKB can help increase clinicians’ confidence in the completeness and accuracy of patient tumor genomic profile information. For translational and clinical researchers, JAX-CKB provides thousands of literature citations, FDA drug labels, and clinical trials relating to the genomic mutational profile of a tumor, providing a clear and up-to-date picture discoveries and active developments for a variety of biomarkers.

“Heligenics’ GigaAssay technology has the potential to advance genomic interpretation, and we are delighted to have the opportunity to provide our users with large-scale interpretation of previously unknown genomic variants, in the hope to connect patients to relevant treatment options that might not have been otherwise identified, ”says Sara Patterson, Ph.D. manager, clinical analysis and curation at JAX.

The benefits of this new collaboration include:

    1) Identify the impact of thousands of poorly understood ERBB2 mutations

    2) Improve understanding of how ERBB2 mutations cause various types of breast and other cancers, including gastric cancer

    3) Test of 95% of possible mutants tested for functional impact in 5 months – a dramatic improvement over the less than 8% of possible ERBB2 mutants characterized after more than 25 years of study

    4) Analyze, in retrospect, how data from the genetic mutation / function library can improve patient outcomes

    5) Provide additional information on breast cancers and other cancers caused by these genetic mutations through research collaboration and publications

“This collaboration with Heligenics will allow us to define new therapeutic targets for cancer patients,” said Jens Rueter, MD, medical director of the Maine Cancer Genomics Initiative at JAX. “Ultimately, this has the potential to lead to new treatment options for cancer patients, including the many cancer patients and families in Maine.”

Heligenics: Heligenics Incorporated, founded in 2018 to discover the function of genetic variants at scale to improve diagnostics and improve clinical trial design for new drug development.

Heligenics’ key technology, GigaAssay, was invented in the lab of Dr. Martin Schiller at the University of Nevada – Las Vegas where he heads the Nevada Institute of Personalized Medicine. As the effect of most mutations on gene function is largely unknown, Heligenics comprehensively measures the functional significance of mutations in the human genome and owns the exclusive rights to the patent pending GigaAssay technology. For more information, please visit http: // www.Heligenics.com

The Jackson Laboratory: Founded in 1929, JAX pioneered the use of mice as models of human disease. As an independent 501 (c) 3 nonprofit biomedical research institution, JAX uniquely integrates its extensive experience in mouse genetics with groundbreaking advancements in human genomics to decipher the biological and genomic causes of human disease. and stimulate medical progress.

Advances in JAX research have formed the basis of modern medicine. Organ and bone marrow transplants, stem cell therapies, and in vitro fertilization all have a basis in JAX research, and at least 26 Nobel Prize winners are associated with JAX research, mouse models, and educational programs.


Warning: AAAS and EurekAlert! are not responsible for the accuracy of any press releases posted on EurekAlert! by contributing institutions or for the use of any information via the EurekAlert system.


About Hector Hedgepeth

Check Also

Experts explain the ‘perfect storm’ of endemic RSV and influenza

The headlines of the past few weeks are sounding the alarm about earlier and more …

Leave a Reply

Your email address will not be published.